RUBIUS THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
RUBIUS THERAPEUTICS INC. - More news...
RUBIUS THERAPEUTICS INC. - More news...
- Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes
- Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
- Rubius Therapeutics Announces Strategic Update
- Rubius Therapeutics to Provide Strategic Update
- Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
- Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
- Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
- Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference
- Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
- Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
- Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability
- Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
- Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
- Rubius Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
- Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results
- Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022
- Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
- Rubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual J.P. Morgan Healthcare Conference
- Rubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
- Rubius Therapeutics to Highlight the Power of its RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day
- Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 3 Best Places to Work in Rhode Island by Providence Business News
- Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021
- Rubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx Conference
- Rubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for Immunotherapy of Cancer’s Annual Meeting
- Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
- Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
- Rubius Therapeutics to Announce Third Quarter 2021 Financial Results
- Rubius Therapeutics Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
- Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference in September 2021
- Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer